Scientists / Our Scientists

Genentech takes the health and safety of our patients, customers, employees and local communities very seriously, and we are actively responding to the global COVID-19 pandemic. For more, please visit our COVID-19 response page or call 1-877-436-3683.

  • A link to this page has been copied to your clipboard.

    https://www.gene.com/scientists/our-scientists/david-hackos

    Paste this link in an email to share.

    Ok
Scientists / Our Scientists
David Hackos - Principal Scientist, Neuroscience

David Hackos

Principal Scientist, Neuroscience

Postdoc Mentor
"My passion is to do great science that will someday result in innovative new medicines that will make patient's lives better."
12
Years at Genentech
32
Publications
4
Awards & Honors

Ever since I was a graduate student at the University of California San Francisco, I have been fascinated by the structure, function, and pharmacology of ion channels. These critical proteins form the functional basis of the nervous system, and without them, our neurons would not be able to send signals down their axons or communicate with each other through synaptic transmission. Despite their importance in physiology, ion channels also make excellent drug targets for a variety of neurological disorders, as long as we can figure out how to target them selectively and in the right way. Currently my lab is leading efforts in the development of novel pain drugs that take advantage on ion channels as targets.

Postdoctoral Mentor

Genentech is a place where you can do science at the highest possible level within a highly multi-disciplinary research environment with cutting-edge infrastructure. The postdoc program at Genentech provides a place for young scientists to dive into this environment and make fundamental contributions to our understanding of the biology of neurological disorders, laying the groundwork for the discovery of the next generation of high-impact therapeutics.

Featured Publication

Positive Allosteric Modulators of GluN2A-Containing NMDARs with Distinct Modes of Action and Impacts on Circuit Function.

Neuron. 2016 Mar 2;89(5):983-99.

Hackos DH, Lupardus P, Wang TM, Chen Y, Reynen P, Gustafson A, Wallweber HA, Volgraf M, Sellers B, Schwarz J, Zhou Q, Paoletti P, Sheng M, Hanson JE.

View Abstract

Structural basis of Nav1.7 inhibition by an isoform-selective small-molecule antagonist.

Science. 2015 Dec 18;350(6267):aac5464.

Ahuja S, Mukund S, Deng L, Khakh K, Chang E, Ho H, Shriver S, Young C, Lin S, Johnson JP Jr, Wu P, Li J, Coons M, Tam C, Brillantes B, Sampang H, Mortara K, Bowman KK, Clark KR, Estevez A, Xie Z, Verschoof H, Grimwood M, Dehnhardt C, Andrez JC, Focken T, Sutherlin DP, Safina BS, Starovasnik MA, Ortwine DF, Franke Y, Cohen CJ, Hackos DH, Koth CM, Payandeh J.

View Abstract

My Focus
Publications
Education
Awards & Honors
© 2021 Genentech, Inc. All rights reserved. This site is intended for US residents only.